ALX Oncology Holdings Files Q3 2024 10-Q
Ticker: ALXO · Form: 10-Q · Filed: Nov 7, 2024 · CIK: 1810182
Sentiment: neutral
Topics: 10-Q, financials, R&D, biotech
TL;DR
ALXO Q3 10-Q filed. R&D expenses detailed. Check fair value & debt investments.
AI Summary
ALX Oncology Holdings Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months ended September 30, 2024. The filing also includes details on fair value measurements and long-term investments in corporate debt securities.
Why It Matters
This filing provides investors with an update on ALX Oncology's financial performance and operational activities for the third quarter of 2024, including R&D spending.
Risk Assessment
Risk Level: medium — Biotech companies like ALX Oncology often face high risks due to the nature of drug development and regulatory hurdles.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the specific quarter the financial data pertains to.)
- 2024-01-01 — R&D Expense Start Date (Marks the beginning of the period for which research and development expenses are reported.)
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-01-01 (date) — Start of the R&D expense reporting period
- 2834 (other) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What were the total research and development expenses for the nine months ended September 30, 2024?
The filing indicates research and development expenses for the period from January 1, 2024, to September 30, 2024, but the specific dollar amount is not provided in this excerpt.
What is ALX Oncology's Standard Industrial Classification code?
ALX Oncology Holdings Inc. is classified under SIC code 2834, which pertains to Pharmaceutical Preparations.
What type of investments does ALX Oncology hold?
The filing mentions long-term investments in corporate debt securities.
What is the company's fiscal year end?
ALX Oncology Holdings Inc.'s fiscal year ends on December 31.
What is the company's primary business address?
The company's business address is 323 Allerton Avenue, South San Francisco, CA 94080.
Filing Stats: 4,335 words · 17 min read · ~14 pages · Grade level 19.2 · Accepted 2024-11-07 16:06:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- alxo-20240930.htm (10-Q) — 2401KB
- alxo-ex10_1.htm (EX-10.1) — 111KB
- alxo-ex31_1.htm (EX-31.1) — 17KB
- alxo-ex31_2.htm (EX-31.2) — 17KB
- alxo-ex32_1.htm (EX-32.1) — 10KB
- alxo-ex32_2.htm (EX-32.2) — 10KB
- 0000950170-24-123290.txt ( ) — 8575KB
- alxo-20240930.xsd (EX-101.SCH) — 1013KB
- alxo-20240930_htm.xml (XML) — 1424KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 32 Item 4
Controls and Procedures
Controls and Procedures 33 PART II OTHER INFORMATION Item 1
Legal Proceedings
Legal Proceedings 34 Item 1A
Risk Factors
Risk Factors 34 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 81 Item 3 Defaults Upon Senior Securities 81 Item 4 Mine Safety Disclosures 81 Item 5 Other Information 81 Item 6 Exhibits 82
— FINANCIAL INFORMATION
PART I — FINANCIAL INFORMATION
Financial Statements (Unaudited)
Item 1. Financial Statements (Unaudited) ALX ONCOLOGY HOLDINGS INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 16,102 $ 22,406 Short-term investments 132,472 160,330 Prepaid expenses and other current assets 7,321 5,923 Total current assets 155,895 188,659 Property and equipment, net 3,112 3,589 Long-term investments 14,036 35,411 Other assets 12,672 14,894 Total assets $ 185,715 $ 242,553 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 7,891 $ 8,591 Payable and accrued liabilities due to related party 63 543 Accrued expenses and other current liabilities 24,386 26,867 Total current liabilities 32,340 36,001 Term loan, non-current 9,835 9,639 Other non-current liabilities 6,733 7,201 Total liabilities 48,908 52,841 Commitments and contingencies (Note 11) Stockholders' equity Common stock, $ 0.001 par value; 1,000,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 52,743,104 and 49,951,989 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 53 50 Additional paid-in capital 728,150 675,678 Accumulated other comprehensive income (loss) 563 256 Accumulated deficit ( 591,959 ) ( 486,272 ) Total stockholders' equity 136,807 189,712 Total liabilities and stockholders' equity $ 185,715 $ 242,553 See accompanying notes to these condensed consolidated financial statements (unaudited). 5 ALX ONCOLOGY HOLDINGS INC. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Operating expenses: Research and d